Company Overview and News

0
ADAP / Adaptimmune Therapeutics plc S-3ASR

2018-07-12 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS
ADAP

8
ADAP / Adaptimmune Therapeutics plc 8-K (Current Report)

2018-07-07 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ADAP

41
ADAP / Adaptimmune Therapeutics plc 8-K (Current Report)

2018-06-20 sec.gov
UNITED STATES SECUR
ADAP

320
A Short Case For A Longer Term!

2018-06-20 seekingalpha
Most investors should favor a longer-term time frame as the markets again record new highs after recovering from the first quarter pullback.
CRC ADAP ECYT LOXO NBIX ARWR SRPT TRXC CHGG SUPN RGNX ARNA TWLO IMMU NDAQ MRTX HEAR TTD

302
ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed

2018-06-13 seekingalpha
Trump-Kim summit has the potential to be market-moving, if adverse, but most likely it will be a non-event.
CRC NKTR DCPH ADAP ECYT LOXO NBIX ARWR SRPT TRXC FOSL SUPN ARNA JNCE IMMU MRTX HEAR TTD

39
Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects

2018-06-11 globenewswire
PHILADELPHIA and OXFORD, United Kingdom, June 11, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that data from the pilot study of NY-ESO SPEAR T‑cells in synovial sarcoma will be published in Cancer Discovery (an American Association of Cancer Research [AACR] publication). Beyond the clinical data, some of which having been reported previously (most recently at CTOS 2017 [https://bit.
ADAP GSK GSK

39
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells

2018-06-04 globenewswire
- No evidence of off-target toxicity at 100 million cells for second wholly owned asset -
ADAP GSK GSK

39
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO

2018-06-04 globenewswire
- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts -
ADAP GSK GSK

39
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile

2018-06-02 globenewswire
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS). With eight patients treated, the best overall responses include three confirmed partial responses, one unconfirmed partial response, three stable disease, and one recently treated patient awaiting assessment.
ADAP GSK GSK

480
Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher

2018-05-31 seekingalpha
The market is becoming more comfortable with risk as evidenced by the rise of the small cap index to a new all-time high.
ECYT AVXS GTHX LOXO ARNA ATRA IMMU BIIB CELG HRTX ADAP REGN AMGN GILD NBIX CRSP SRPT ARIA SUPN SNY CBIO JNJ MRTX NVS BGNE IRR CLSD PFE

252
The Kite Killer - TapImmune And Marker Merger Challenges Gilead

2018-05-30 seekingalpha
Gilead must address 95% grade 3 SAE’s with astrategic license or acquisition of a galectin blocker.
SGEN UMRX NKTR BLCM ADAP GILD GALTW GALTU GALT TPIV MRK CELG IOVA NVS KITE BMY

248
The Kite Killer - TapImmune And Marker Merger Challenge Gilead

2018-05-30 seekingalpha
Gilead must address 95% grade 3 SAE’s with astrategic license or acquisition of a galectin blocker.
SGEN UMRX NKTR BLCM ADAP GILD GALTW GALTU GALT TPIV MRK CELG IOVA NVS KITE BMY

39
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting

2018-05-16 globenewswire
PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical studies at the annual ASCO meeting at McCormick Place in Chicago, Illinois.
ADAP GSK GSK

149
Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares

2018-05-15 cnbc
Bristol-Myers Squibb: "Bristol-Myers right now does not have what we're looking for in terms of that cancer franchise that's going to Merck. I've got to tell you, down here, with a 3 percent yield, it gets attractive. But because of interest rates going higher, I'm going to have to take a pass for the moment."
CKRGZ AEP.PRA ADAP CHKVP LB CHKDH CHKVZ IEP SE CHKDG CHKWZ CHKDJ CHKDP CHK.WI CHK AEP CHK.PRD ED

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

Silicon Investor Message Boards

This table lists all message boards related to ADAP / Adaptimmune Therapeutics plc on message board site Silicon Investor.

Adaptive Broadband (NASDAQ:ADAP) Adaptec (ADPT)
Impinj: SelfAdaptive Semiconductor SectorTalk - Wireless Broadband - MMDS, Satellite, LMDS
IOMC: The Next Adaptec? ADAP Board
ADSOD-Adaptive solutions
CUSIP: 00653A107